ICD-10-CM Billable Code

C50.322

Malignant neoplasm of lower-inner quadrant of left male breast

Clinical Classification Guidelines

Medical Intelligence & Overview

The ICD-10 code C50.322 refers to a malignant tumor located in the lower-inner quadrant of the left breast in males. This type of breast cancer falls under the broader category of male breast cancers, which are relatively rare compared to female breast cancer. Malignant neoplasms are cancerous growths that can invade surrounding tissues and spread to other parts of the body if not diagnosed and treated promptly. The specific location within the breast, such as the lower-inner quadrant, can influence treatment options and prognosis.

Causes & Symptoms

Clinical Causes: - G e n e t i c m u t a t i o n s a n d f a m i l i a l p r e d i s p o s i t i o n - I n h e r i t e d g e n e m u t a t i o n s l i k e B R C A 1 a n d B R C A 2 - H o r m o n a l i m b a l a n c e s t h a t i n c r e a s e b r e a s t t i s s u e e x p o s u r e t o e s t r o g e n - R a d i a t i o n e x p o s u r e t o t h e c h e s t a r e a - A g e , w i t h h i g h e r r i s k a s m e n g r o w o l d e r - P e r s o n a l h i s t o r y o f b r e a s t c a n c e r o r o t h e r c a n c e r s - O b e s i t y , w h i c h c a n l e a d t o i n c r e a s e d e s t r o g e n l e v e l s - L i v e r d i s e a s e , a f f e c t i n g h o r m o n e m e t a b o l i s m - C e r t a i n g e n e t i c s y n d r o m e s , s u c h a s K l i n e f e l t e r s y n d r o m e

Key Symptoms: - A p a i n l e s s l u m p o r t h i c k e n i n g i n t h e b r e a s t o r c h e s t w a l l - C h a n g e s i n t h e s i z e , s h a p e , o r a p p e a r a n c e o f t h e b r e a s t - S k i n c h a n g e s o n t h e b r e a s t , s u c h a s r e d n e s s , d i m p l i n g , o r p u c k e r i n g - N i p p l e c h a n g e s , i n c l u d i n g i n v e r s i o n , d i s c h a r g e , o r s k i n e r o s i o n - S w e l l i n g o r a m a s s f e e l i n g i n t h e c h e s t a r e a - U n e x p l a i n e d p a i n o r t e n d e r n e s s i n t h e b r e a s t o r c h e s t - I t c h i n g o r s k i n u l c e r a t i o n i n a d v a n c e d s t a g e s

Diagnostic & Treatment

Diagnosis Path: Diagnosis of this specific type of breast cancer involves several steps: - Physical examination: Assessing the breast and chest area for lumps or abnormal skin changes. - Imaging tests: Mammography, ultrasound, or MRI scans to visualize the tumor. - Biopsy: Collecting tissue samples from the suspected tumor to determine if it is cancerous and its histological type. - Additional tests: Blood tests and imaging studies such as CT scans or bone scans to check for metastasis. - Hormone receptor testing: Analyzing tumor tissue for hormone receptor status to guide treatment options.

Treatment Protocols: Treatment strategies for malignant neoplasm of the lower-inner quadrant of the left male breast typically include: - Surgery: Commonly a mastectomy or breast-conserving surgery, depending on tumor size and location. - Radiation therapy: To target residual cancer cells in the breast area. - Chemotherapy: To target cancer cells systemically and reduce the risk of recurrence. - Hormonal therapy: For hormone receptor-positive tumors, medications like tamoxifen may be recommended. - Targeted therapy: Use of drugs that specifically target molecular characteristics of the tumor. - Follow-up and monitoring: Regular check-ups to detect any signs of recurrence or metastasis. The specific treatment plan will be tailored to the patient’s overall health, tumor features, and personal preferences.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C50.322 a billable ICD-10 code?
Yes, C50.322 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C50.322?
Clinical documentation must specify the nature of Malignant neoplasm of lower-inner quadrant of left male breast and any associated comorbidities for accurate reporting.

Cite this Clinical Reference